Celltrion Brasil

What Celltrion Brasil does

Celltrion Brasil (legal name: Celltrion Healthcare Distribuição de Produtos Farmacêuticos do Brasil Ltda) is a São Paulo-based private limited company and wholly-owned Brazilian subsidiary of South Korean biopharmaceutical company Celltrion Inc. Founded in 2012 and employing approximately 28 people, the entity markets and distributes a portfolio of seven approved monoclonal antibody biosimilars in Brazil: Herzuma (trastuzumab, HER2-positive breast cancer), Remsima and Remsima SC (infliximab, autoimmune disease), Truxima (rituximab, hematologic malignancies and autoimmune disorders), Vegzelma (bevacizumab, multiple oncology indications), Yuflyma (adalimumab, autoimmune disease), and Omlyclo (omalizumab, asthma and urticaria). Five of these products carry ANVISA approval. The subsidiary also supports patients through the 'Celltrion com Você' program and maintains a Phase 3 pipeline of five biosimilar candidates (CT-P39, CT-P44, CT-P51, CT-P53, CT-P55) targeting additional oncology, immunology, and respiratory indications.

The underlying technology platform is supplied by the parent, which operates three South Korean manufacturing facilities totaling 250,000 liters of annual production capacity certified by the FDA, EMA, and MFDS. Parent-level capabilities include proprietary animal cell culture technology designated as National Core Technology in Korea, high-expression cell line development, antibody-drug conjugate (ADC) platforms, multispecific antibody engineering, mRNA technology, microbiome-based live biotherapeutic products, subcutaneous formulation development, and Analytical Quality by Design (A-QbD). Twenty percent of parent revenue is reinvested in R&D, and 33% of employees hold master's or doctoral degrees.

Celltrion Brasil operates a direct enterprise sales motion targeting hospitals, oncology centers, clinics, and prescribing physicians (oncologists, rheumatologists, immunologists) across Brazil. Following a transition from exclusive distributor Biomm S.A. that began in October 2024, the entity now sells directly, while the parent retains global distribution partnerships with Pfizer, Teva, Hikma, and other regional distributors in markets outside the direct coverage footprint. Pricing is quote-based and not publicly disclosed. Revenue is generated through biosimilar product sales; specific revenue figures for the Brazilian entity are not disclosed in the source data.

Name

Celltrion Brasil

Legal name

Celltrion Healthcare Distribuição de Produtos Farmacêuticos do Brasil Ltda

Website

https://celltrion.com.br

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Celltrion Brasil is the São Paulo-based wholly-owned subsidiary of South Korean biopharmaceutical firm Celltrion Inc., distributing seven ANVISA-approved monoclonal antibody biosimilars across oncology, autoimmune, and respiratory indications to Brazilian hospitals, oncology centers, and prescribing physicians through direct sales.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals / Biosimilars

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAIAJAH

Biologics & Biosimilars Distributors

Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

SECONDARYHLAAAHAG

Oncology Biosimilars

Healthcare & Life Sciences/Biotechnology & Biologics/Biosimilars & Biologic Generics

SECONDARYHLAIACAB

Immunology & Autoimmune Specialty Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

Keywords

• Biopharmaceutical products
• Monoclonal antibody biosimilars
• Oncology therapeutics
• Autoimmune disease treatments
• Biologic drug manufacturing

Headquarters

HQ city

Incheon

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Biosimilar Sales: Revenue generated from the sale of biosimilar products including monoclonal antibodies (mAbs) for the treatment of cancer, autoimmune diseases, and other conditions. Products include Herzuma (trastuzumab), Remsima (infliximab), Truxima (rituximab), Vegzelma (bevacizumab), Yuflyma (adalimumab), and Omlyclo (omalizumab).

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Celltrion Brasil is the Brazilian subsidiary of Celltrion Inc., distributing and commercializing a portfolio of approved biosimilar monoclonal antibody (mAb) products including Herzuma (trastuzumab), Remsima (infliximab), Remsima SC, Truxima (rituximab), Vegzelma (bevacizumab), Yuflyma (adalimumab), and Omlyclo (omalizumab). The company sells these biologic pharmaceuticals to hospitals, clinics, oncology centers, and healthcare institutions in Brazil for the treatment of HER2-positive breast cancer, autoimmune diseases, asthma, urticaria, and various other conditions. The entity also operates the Celltrion com Você patient support program to assist Brazilian patients with access and treatment continuity.

Product overview

Celltrion Brasil is the Brazilian subsidiary of Celltrion, a global biopharmaceutical company and the developer of the world's first monoclonal antibody biossimilar. The company offers a portfolio of 7 approved antibody biossimilar products: Herzuma™ (Trastuzumab), Remsima™ and Remsima™ SC (Infliximab), Truxima™ (Rituximab), Vegzelma™ (Bevacizumab), Yuflyma™ (Adalimumabe), and Omlyclo™ (Omalizumab). The portfolio covers treatments for oncology (breast cancer, melanoma, lung cancer), autoimmune diseases (rheumatoid arthritis, psoriasis, multiple sclerosis), and respiratory conditions (asthma, urticaria). Additionally, the company maintains a robust pipeline of 5 biossimilar candidates in Phase 3 clinical trials (CT-P39, CT-P44, CT-P51, CT-P53, CT-P55) targeting conditions including asthma, multiple myeloma, melanoma, lung cancer, multiple sclerosis, and psoriasis. The company also develops advanced technology platforms including ADC (Antibody-Drug Conjugates), multispecific antibodies, mRNA, microbiome therapeutics, and subcutaneous formulations. Celltrion Brasil supports patients through its Celltrion com Você patient support program.

Differentiator

Problem solved

Functional benefit

Products and services

• Herzuma Biosimilar of trastuzumab (150mg and 440mg) for the treatment of HER2-positive breast cancer. Approved by ANVISA (Brazil), FDA (USA), EMA (EU), and MFDS (Korea).
• Remsima Biosimilar of infliximab (100mg IV formulation) for autoimmune disease treatment. Approved by ANVISA, FDA, EMA, and MFDS.
• Remsima SC Subcutaneous formulation of Remsima (120mg) providing more convenient administration for patients. Approved by MFDS (Korea).
• Truxima Biosimilar of rituximab (100mg and 500mg) for the treatment of hematologic malignancies and autoimmune disorders. Approved by ANVISA, FDA, EMA, and MFDS.
• Vegzelma Biosimilar of bevacizumab (100mg and 400mg) for the treatment of various cancers including colorectal, lung, breast, kidney, and cervical cancers. Approved by ANVISA, FDA, EMA, and MFDS.
• Yuflyma Biosimilar of adalimumab (40mg and 80mg) for the treatment of autoimmune diseases including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Approved by ANVISA, FDA, EMA, and MFDS.
• Omlyclo Biosimilar of omalizumab (75mg and 150mg) for the treatment of asthma and chronic urticaria. Approved by EMA (EU) and FDA (USA).
• Celltrion com Você Patient support program providing assistance with medication access, education, and treatment support for patients using Celltrion products in Brazil.

Quantifiable outcome

• 99%+ cumulative production success rate with zero contamination and zero accidents
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

14 partnerships are on record, tiered major, core and minor.

• Biomm S.A.majorChannel Partner/ Reseller/ Distributor · 1 January 2017Former exclusive distributor of Herzuma® (trastuzumab 440mg) in Brazil from 2017. Transition to direct distribution by Celltrion Healthcare do Brasil began in October 2024 as part of Celltrion's Latin America internalization strategy.
• PfizermajorChannel Partner/ Reseller/ DistributorGlobal distribution partner for Celltrion biosimilar products in select markets.
• TevamajorChannel Partner/ Reseller/ DistributorGlobal pharmaceutical partner for distribution of biosimilar products in various territories.
• HikmamajorChannel Partner/ Reseller/ DistributorGlobal pharmaceutical distribution partner for biosimilar products in Middle East and North Africa regions.
• Orion PharmacoreChannel Partner/ Reseller/ DistributorNordic region distribution partner for Celltrion pharmaceutical products.
• Kern Pharma BiologicscoreChannel Partner/ Reseller/ DistributorSpain-based distribution partner for biosimilar products.
• iQOne Healthcare SwitzerlandcoreChannel Partner/ Reseller/ DistributorSwitzerland-based healthcare distribution partner.
• Adcock IngramcoreChannel Partner/ Reseller/ DistributorSouth African pharmaceutical distribution partner.
• Vianex S.A.coreChannel Partner/ Reseller/ DistributorGreek pharmaceutical manufacturer and distributor, member of Giannakopoulos Group.
• Astro PharmaminorChannel Partner/ Reseller/ DistributorRegional pharmaceutical distribution partner.
• MediPharm LabsminorChannel Partner/ Reseller/ DistributorPharmaceutical distribution partner.
• George Steuart HealthminorChannel Partner/ Reseller/ DistributorSri Lankan pharmaceutical and healthcare distribution partner.
• PadagisminorChannel Partner/ Reseller/ DistributorPharmaceutical products distribution partner.
• Atco PharmaminorChannel Partner/ Reseller/ DistributorRegional pharmaceutical distribution partner.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Regional players

• EMS Pharma: Largest Brazilian pharmaceutical company by units sold, with a growing biosimilars and specialty biologics portfolio. Comparable because it competes with Celltrion Brasil for ANVISA-approved biosimilar share through SUS tenders and hospital channels.
• Eurofarma Laboratórios: Brazilian multinational pharma with significant investments in biologics and biosimilars. Comparable as a Latin American specialty/biologics player pursuing similar hospital and oncology channels as Celltrion Brasil.
• Aché Laboratórios: Major Brazilian pharmaceutical company expanding into specialty and biologic therapies. Comparable because it targets overlapping prescriber bases (oncologists, rheumatologists, dermatologists) and competes for biologic prescription share in Brazil.
• Cristália: Brazilian pharmaceutical manufacturer with biotech capabilities and a presence in oncology and autoimmune products. Comparable as a domestically-based biosimilar/specialty competitor in the same Brazilian hospital channels.

Direct peers

• Samsung Bioepis: Korean biosimilar developer (Samsung Biologics + Biogen JV) competing head-to-head with Celltrion in mAb biosimilars including infliximab, adalimumab, and trastuzumab. Comparable as the closest direct Korean biosimilar rival whose portfolio overlaps Celltrion Brasil's.
• Biomm S.A. Brazilian biotech that was Celltrion's exclusive distributor for Herzuma in Brazil until October 2024. Comparable because it operates in the same biologics/biosimilars distribution space in Brazil and represents the most direct channel competitor for Celltrion Brasil's oncology franchise.

Broad incumbents

• Pfizer: Global biopharma incumbent that is also a Celltrion distribution partner in other markets but competes directly with its own oncology and autoimmune biologics in Brazil. Comparable as the dominant multinational reference-product owner whose molecules Celltrion's biosimilars target.
• Sandoz: Novartis's biosimilars-focused division and the global biosimilar market leader. Comparable as the most established pure-play biosimilar competitor in Brazil and globally, with overlapping infliximab, rituximab, adalimumab, and oncology biosimilar SKUs.
• Amgen: Global biotechnology leader with both reference biologics and an emerging biosimilars portfolio. Comparable as a multinational competitor whose oncology and autoimmune reference biologics (rituximab, trastuzumab, bevacizumab, adalimumab) are the same targets as Celltrion's Brazilian biosimilars.

Emerging players

• Biocon: India-based global biopharmaceutical company with a portfolio of biosimilars including trastuzumab, pegfilgrastim, and insulin analogs. Comparable as another emerging-market biosimilar developer with ANVISA-relevant approvals and similar oncology/autoimmune focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/celltrion-brasil

Compliance11 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celltrion Brasil